Catalent Management

Management criteria checks 1/4

Catalent's CEO is Alessandro Maselli, appointed in Jul 2022, has a tenure of 2.33 years. total yearly compensation is $9.99M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 0.021% of the company’s shares, worth €2.04M. The average tenure of the management team and the board of directors is 1.5 years and 9.3 years respectively.

Key information

Alessandro Maselli

Chief executive officer

US$10.0m

Total compensation

CEO salary percentage	9.3%
CEO tenure	2.3yrs
CEO ownership	0.02%
Management average tenure	1.5yrs
Board average tenure	9.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Alessandro Maselli's remuneration changed compared to Catalent's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	US$10m	US$925k	-US$1b
Mar 31 2024	n/a	n/a	-US$1b
Dec 31 2023	n/a	n/a	-US$1b
Sep 30 2023	n/a	n/a	-US$1b
Jun 30 2023	US$7m	US$925k	-US$256m
Mar 31 2023	n/a	n/a	US$21m
Dec 31 2022	n/a	n/a	US$389m
Sep 30 2022	n/a	n/a	US$399m
Jun 30 2022	US$3m	US$654k	US$483m
Mar 31 2022	n/a	n/a	US$485m
Dec 31 2021	n/a	n/a	US$561m
Sep 30 2021	n/a	n/a	US$544m
Jun 30 2021	US$5m	US$640k	US$529m
Mar 31 2021	n/a	n/a	US$494m
Dec 31 2020	n/a	n/a	US$289m
Sep 30 2020	n/a	n/a	US$250m
Jun 30 2020	US$3m	US$483k	US$173m
Mar 31 2020	n/a	n/a	US$104m
Dec 31 2019	n/a	n/a	US$124m
Sep 30 2019	n/a	n/a	US$138m
Jun 30 2019	US$2m	US$450k	US$132m

Compensation vs Market: Alessandro's total compensation ($USD9.99M) is above average for companies of similar size in the German market ($USD5.20M).

Compensation vs Earnings: Alessandro's compensation has increased whilst the company is unprofitable.

CEO

Alessandro Maselli (52 yo)

2.3yrs

Tenure

US$9,985,363

Compensation

Mr. Alessandro Maselli has been President of Catalent Pharma Solutions, Inc. from February 2019 and serves as its Director since July 01, 2022 and is its Chief Executive Officer and was its Chief Operation...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
John Greisch	Executive Chairman of the Board	6.8yrs	US$5.28m	0.024% € 2.3m
Alessandro Maselli	President	2.3yrs	US$9.99m	0.021% € 2.0m
Matti Masanovich	Senior VP & CFO	1.3yrs	US$6.65m	0.0051% € 500.0k
Lisa Evoli	Senior VP & Chief Human Resources Officer	1.3yrs	US$2.84m	0.0030% € 293.0k
Ricky Hopson	President	1.3yrs	US$1.55m	0.0065% € 633.8k
David McErlane	Group President of Biologics Segment	1.2yrs	US$2.52m	0.0024% € 234.4k
Michael Hatzfeld	VP & Chief Accounting Officer	less than a year	no data	no data
Charles Lickfold	Senior VP & Chief Information Officer	4.5yrs	no data	0.0060% € 586.0k
Paul Surdez	Vice President of Investor Relations	4.8yrs	no data	no data
Joseph Ferraro	Senior VP	1.8yrs	no data	0.00093% € 90.8k
Michael Grippo	Senior Vice President of Strategy & Corporate Development	5.1yrs	no data	0.013% € 1.3m
Aristippos Gennadios	Group President of Pharma & Consumer Health Segment	5.8yrs	US$3.80m	0.063% € 6.1m

1.5yrs

Average Tenure

52yo

Average Age

Experienced Management: 0C8's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
John Greisch	Executive Chairman of the Board	6.8yrs	US$5.28m	0.024% € 2.3m
Alessandro Maselli	President	2.3yrs	US$9.99m	0.021% € 2.0m
Donald Morel	Independent Director	9yrs	US$376.42k	0.030% € 2.9m
Rolf Classon	Independent Director	10.3yrs	US$364.18k	0.0061% € 595.8k
Daniel R. Marshak	Member of Advisory Board	9.3yrs	no data	no data
Jack Stahl	Independent Lead Director	10.3yrs	US$439.57k	0.015% € 1.5m
Gregory Lucier	Independent Director	9.6yrs	US$400.12k	0.00077% € 75.2k
J. Carroll	Independent Director	9.3yrs	US$419.62k	0.022% € 2.1m
Edward Robinson	Member of Advisory Board	9.6yrs	no data	no data
Michael Buckley	Member of Advisory Board	9.3yrs	no data	no data
Carolyn Bertozzi	Member of Scientfic & Advisory Board	9.3yrs	no data	no data
Barry Buckland	Member of Advisory Board	9.3yrs	no data	no data

9.3yrs

Average Tenure

67yo

Average Age

Experienced Board: 0C8's board of directors are considered experienced (9.3 years average tenure).

Catalent Management

Management criteria checks 1/4

Key information

Recent management updates

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. Announces Board Changes

Recent updates

Catalent, Inc. announced delayed annual 10-K filing

Full year 2024 earnings released: US$5.76 loss per share (vs US$1.41 loss in FY 2023)

New minor risk - Insider selling

Insufficient new directors

Catalent, Inc. announced delayed 10-Q filing

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Novo Holdings A/S entered into an agreement to acquire Catalent, Inc. (NYSE:CTLT) from Elliott Investment Management L.P. and other for $11.7 million.

Catalent, Inc. to Report Q2, 2024 Results on Feb 09, 2024

Catalent, Inc. Announces Executive Changes

Catalent, Inc., Annual General Meeting, Jan 25, 2024

Catalent, Inc. Reaffirms Earnings Guidance for the Fiscal Year 2024

Catalent, Inc. announced delayed 10-Q filing

Catalent, Inc. to Report Q1, 2024 Results on Nov 15, 2023

Catalent, Inc. Appoints David McErlane as Group President of Catalent’s Biologics segment, Effective September 25, 2023

Catalent Receives NYSE Notice Regarding Late Form 10-K Filing

Catalent, Inc. Appoints Steven Barg as A Member of the Board of Directors

Catalent, Inc. announced delayed annual 10-K filing

Full year 2023 earnings released: US$1.28 loss per share (vs US$2.74 profit in FY 2022)

Catalent, Inc. Announces Board Changes

Catalent, Inc. to Report Q4, 2023 Results on Aug 29, 2023

Insufficient new directors

Catalent, Inc. Announces Executive Changes

Catalent, Inc.(NYSE:CTLT) dropped from Russell 1000 Growth Index

Catalent, Inc. Appoints Matti Masanovich as Senior Vice President, Effective July 5, 2023

Catalent Regains Compliance with NYSE Continued Listing Standards

Catalent, Inc. Reports Impairment Results for the Quarter Ended March 31, 2023

Catalent, Inc. Updates Revenue Guidance for the Full Year of 2023

Catalent, Inc. announced delayed 10-Q filing

Now 37% undervalued after recent price drop

Catalent, Inc. Reduces Revenue Guidance for the Fiscal Year 2023

Insider recently sold €66k worth of stock

Investor sentiment improves as stock rises 18%

Now 22% undervalued after recent price drop

Catalent Appoints Joseph A. Ferraro as Senior Vice President, General Counsel, Chief Compliance Officer, and Secretary

Catalent, Inc. Reiterates Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.45 (vs US$0.51 in 2Q 2022)

Danaher Reportedly Expresses Takeover Interest in Catalent

Investor sentiment improves as stock rises 36%

Catalent, Inc. to Report Q2, 2023 Results on Feb 07, 2023

Now 20% undervalued after recent price drop

Catalent, Inc. Announces the Appointment of Ricardo Zayas as Senior Vice President, Operations, Biologics North America

Catalent, Inc. Announces Director Changes

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

Insider recently sold €163k worth of stock

First quarter 2023 earnings released

Catalent, Inc. Revises Revenue Guidance for the Full Year 2023

Catalent, Inc. to Report Q1, 2023 Results on Nov 01, 2022

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Catalent, Inc. Appoints Karen Santiago as Chief Accounting Officer

Now 21% undervalued after recent price drop

Catalent, Inc., Annual General Meeting, Oct 27, 2022

Full year 2022 earnings released: EPS: US$2.86 (vs US$3.15 in FY 2021)

Catalent, Inc. Appoints Karen Flynn to Board of Directors, Effective September 15, 2022

Executive Chair of the Board recently sold €4.0m worth of stock

Catalent, Inc. (NYSE:CTLT) agreed to acquire Metrics, Inc. from Mayne Pharma (USA), Inc. for $475 million.

Catalent, Inc. to Report Q4, 2022 Results on Aug 29, 2022

Executive Chair of the Board recently sold €1.0m worth of stock

Catalent, Inc. Announces Board Changes

Catalent, Inc. Raises Revenue Guidance for the Full Year of 2022

Third quarter 2022 earnings released: EPS: US$0.78 (vs US$1.27 in 3Q 2021)

Insufficient new directors

Catalent, Inc. (NYSE:CTLT) acquired Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. (NYSE:CTLT) entered into an asset purchase agreement to acquire Cell therapy manufacturing facility in Princeton, New Jersey of ERYTECH Pharma S.A. (ENXTPA:ERYP) for $44.5 million.

Catalent, Inc. to Report Q3, 2022 Results on May 03, 2022

Catalent, Inc. revises Earnings Guidance for the Fiscal Year 2022

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Independent Director recently sold €573k worth of stock